Last reviewed · How we verify
Ocriplasmin 25µg
At a glance
| Generic name | Ocriplasmin 25µg |
|---|---|
| Also known as | Microplasmin |
| Sponsor | ThromboGenics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III) (PHASE2)
- A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocriplasmin 25µg CI brief — competitive landscape report
- Ocriplasmin 25µg updates RSS · CI watch RSS
- ThromboGenics portfolio CI